Literature DB >> 16988228

Passive immunization with a multicomponent vaccine against conserved domains of apical membrane antigen 1 and 235-kilodalton rhoptry proteins protects mice against Plasmodium yoelii blood-stage challenge infection.

David L Narum1, Solabomi A Ogun, Adrian H Batchelor, Anthony A Holder.   

Abstract

During malaria parasite invasion of red blood cells, merozoite proteins bind receptors on the surface of the erythrocyte. Two candidate Plasmodium yoelii adhesion proteins are apical membrane antigen 1 (AMA1) and the 235-kDa rhoptry proteins (P235). Previously, we have demonstrated that passive immunization with monoclonal antibodies (MAbs) 45B1 and 25.77 against AMA1 and P235, respectively, protects against a lethal challenge infection with P. yoelii YM. We show that MAb 45B1 recognizes an epitope located on a conserved surface of PyAMA1, as determined by phage display and analysis of the three-dimensional structure of AMA1, in a region similar to that bound by the P. falciparum AMA1-specific inhibitory antibody 4G2. The epitope recognized by 25.77 could not be assigned. We report here that MAbs 45B1 and 25.77 also protect against challenge with the nonlethal parasite line 17X, in which PyAMA1 has a significantly different amino acid sequence from that in YM. When administered together, the two MAbs acted at least additively in providing protection against challenge with the virulent YM parasite. These results support the concept of developing a multicomponent blood-stage vaccine and the inclusion of polymorphic targets such as AMA1, which these results suggest contain conserved domains recognized by inhibitory antibodies.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16988228      PMCID: PMC1594904          DOI: 10.1128/IAI.00573-06

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  58 in total

1.  Sudden increase in virulence in a strain of Plasmodium berghei yoelii.

Authors:  M Yoeli; B Hargreaves; R Carter; D Walliker
Journal:  Ann Trop Med Parasitol       Date:  1975-06

2.  Vaccination trials in rhesus monkeys with a minor, invariant, Plasmodium knowlesi 66 kD merozoite antigen.

Authors:  J A Deans; A M Knight; W C Jean; A P Waters; S Cohen; G H Mitchell
Journal:  Parasite Immunol       Date:  1988-09       Impact factor: 2.280

3.  Rat monoclonal antibodies which inhibit the in vitro multiplication of Plasmodium knowlesi.

Authors:  J A Deans; T Alderson; A W Thomas; G H Mitchell; E S Lennox; S Cohen
Journal:  Clin Exp Immunol       Date:  1982-08       Impact factor: 4.330

4.  Immunization against blood-stage rodent malaria using purified parasite antigens.

Authors:  A A Holder; R R Freeman
Journal:  Nature       Date:  1981-11-26       Impact factor: 49.962

5.  Vaccination of monkeys with recombinant Plasmodium falciparum apical membrane antigen 1 confers protection against blood-stage malaria.

Authors:  Anthony W Stowers; Michael C Kennedy; Brian P Keegan; Allan Saul; Carole A Long; Louis H Miller
Journal:  Infect Immun       Date:  2002-12       Impact factor: 3.441

6.  Expression, crystallization and preliminary structural analysis of the ectoplasmic region of apical membrane antigen 1 from Plasmodium vivax, a malaria-vaccine candidate.

Authors:  Brigitte Vulliez-Le Normand; Juan Carlos Pizarro; Marie Laure Chesne-Seck; Clemens H M Kocken; Bart Faber; Alan W Thomas; Graham A Bentley
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2004-10-20

7.  Phase 1 randomized double-blind safety and immunogenicity trial of Plasmodium falciparum malaria merozoite surface protein FMP1 vaccine, adjuvanted with AS02A, in adults in western Kenya.

Authors:  José A Stoute; Joash Gombe; Mark R Withers; Joram Siangla; Denise McKinney; Melanie Onyango; James F Cummings; Jessica Milman; Kathryn Tucker; Lorraine Soisson; V Ann Stewart; Jeffrey A Lyon; Evelina Angov; Amanda Leach; Joe Cohen; Kent E Kester; Christian F Ockenhouse; Carolyn A Holland; Carter L Diggs; Janet Wittes; D Gray Heppner
Journal:  Vaccine       Date:  2005-12-07       Impact factor: 3.641

8.  Apical membrane antigen 1, a major malaria vaccine candidate, mediates the close attachment of invasive merozoites to host red blood cells.

Authors:  G H Mitchell; A W Thomas; G Margos; A R Dluzewski; L H Bannister
Journal:  Infect Immun       Date:  2004-01       Impact factor: 3.441

9.  Protective monoclonal antibodies recognising stage-specific merozoite antigens of a rodent malaria parasite.

Authors:  R R Freeman; A J Trejdosiewicz; G A Cross
Journal:  Nature       Date:  1980-03-27       Impact factor: 49.962

10.  The Fab fragments of monoclonal IgG to a merozoite surface antigen inhibit Plasmodium knowlesi invasion of erythrocytes.

Authors:  A W Thomas; J A Deans; G H Mitchell; T Alderson; S Cohen
Journal:  Mol Biochem Parasitol       Date:  1984-10       Impact factor: 1.759

View more
  14 in total

1.  Production of Plasmodium vivax enolase in Escherichia coli and its protective properties.

Authors:  Chao Zhang; Yaping Gu; Jianxia Tang; Feng Lu; Yuanyuan Cao; Huayun Zhou; Guoding Zhu; Jun Cao; Qi Gao
Journal:  Hum Vaccin Immunother       Date:  2016-08-03       Impact factor: 3.452

2.  Acquired antibodies to merozoite antigens in children from Uganda with uncomplicated or severe Plasmodium falciparum malaria.

Authors:  Hodan Ahmed Ismail; Ulf Ribacke; Linda Reiling; Johan Normark; Tom Egwang; Fred Kironde; James G Beeson; Mats Wahlgren; Kristina E M Persson
Journal:  Clin Vaccine Immunol       Date:  2013-06-05

3.  Structural characterization of apical membrane antigen 1 (AMA1) from Toxoplasma gondii.

Authors:  Joanna Crawford; Michelle L Tonkin; Ognjen Grujic; Martin J Boulanger
Journal:  J Biol Chem       Date:  2010-03-19       Impact factor: 5.157

4.  Interaction between Plasmodium falciparum apical membrane antigen 1 and the rhoptry neck protein complex defines a key step in the erythrocyte invasion process of malaria parasites.

Authors:  Dave Richard; Christopher A MacRaild; David T Riglar; Jo-Anne Chan; Michael Foley; Jake Baum; Stuart A Ralph; Raymond S Norton; Alan F Cowman
Journal:  J Biol Chem       Date:  2010-03-12       Impact factor: 5.157

5.  Protective properties and surface localization of Plasmodium falciparum enolase.

Authors:  Ipsita Pal-Bhowmick; Monika Mehta; Isabelle Coppens; Shobhona Sharma; Gotam K Jarori
Journal:  Infect Immun       Date:  2007-09-04       Impact factor: 3.441

6.  Identification and characterization of the Plasmodium yoelii PyP140/RON4 protein, an orthologue of Toxoplasma gondii RON4, whose cysteine-rich domain does not protect against lethal parasite challenge infection.

Authors:  David L Narum; Vu Nguyen; Yanling Zhang; Jacqueline Glen; Richard L Shimp; Lynn Lambert; Irene T Ling; Karine Reiter; Solabomi A Ogun; Carole Long; Anthony A Holder; Raul Herrera
Journal:  Infect Immun       Date:  2008-08-18       Impact factor: 3.441

7.  Targeting essential Eimeria ninakohlyakimovae sporozoite ligands for caprine host endothelial cell invasion with a phage display peptide library.

Authors:  A Ruiz; D Pérez; M C Muñoz; J M Molina; A Taubert; M Jacobs-Lorena; J Vega-Rodríguez; A M López; C Hermosilla
Journal:  Parasitol Res       Date:  2015-09-05       Impact factor: 2.289

8.  Phase 1 study in malaria naïve adults of BSAM2/Alhydrogel®+CPG 7909, a blood stage vaccine against P. falciparum malaria.

Authors:  Ruth D Ellis; Yimin Wu; Laura B Martin; Donna Shaffer; Kazutoyo Miura; Joan Aebig; Andrew Orcutt; Kelly Rausch; Daming Zhu; Anders Mogensen; Michael P Fay; David L Narum; Carole Long; Louis Miller; Anna P Durbin
Journal:  PLoS One       Date:  2012-10-04       Impact factor: 3.240

9.  Humoral immune response to mixed PfAMA1 alleles; multivalent PfAMA1 vaccines induce broad specificity.

Authors:  Kwadwo A Kusi; Bart W Faber; Alan W Thomas; Edmond J Remarque
Journal:  PLoS One       Date:  2009-12-01       Impact factor: 3.240

10.  An inhibitory antibody blocks interactions between components of the malarial invasion machinery.

Authors:  Christine R Collins; Chrislaine Withers-Martinez; Fiona Hackett; Michael J Blackman
Journal:  PLoS Pathog       Date:  2009-01-23       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.